Atai Life Sciences Past Earnings Performance
Past criteria checks 0/6
Atai Life Sciences has been growing earnings at an average annual rate of 12.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 58.3% per year.
Key information
12.3%
Earnings growth rate
33.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -58.3% |
| Return on equity | -89.0% |
| Net Margin | -38,852.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Psychedelic Stock Deep Dive: Atai Life Sciences
Sep 03Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15
ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Revenue & Expenses Breakdown
How Atai Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -129 | 54 | 50 |
| 30 Jun 24 | 0 | -58 | 56 | 49 |
| 31 Mar 24 | 0 | -34 | 61 | 54 |
| 31 Dec 23 | 0 | -40 | 62 | 60 |
| 30 Sep 23 | 0 | -67 | 58 | 69 |
| 30 Jun 23 | 0 | -145 | 66 | 76 |
| 31 Mar 23 | 0 | -149 | 65 | 76 |
| 31 Dec 22 | 0 | -152 | 70 | 74 |
| 30 Sep 22 | 0 | -196 | 81 | 65 |
| 30 Jun 22 | 1 | -194 | 81 | 60 |
| 31 Mar 22 | 0 | -205 | 101 | 58 |
| 31 Dec 21 | 20 | -168 | 93 | 48 |
| 30 Sep 21 | 20 | -166 | 139 | 38 |
| 30 Jun 21 | 20 | -218 | 123 | 33 |
| 31 Mar 21 | 20 | -185 | 88 | 15 |
| 31 Dec 20 | 0 | -170 | 81 | 11 |
Quality Earnings: ATAI is currently unprofitable.
Growing Profit Margin: ATAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATAI is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare ATAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATAI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ATAI has a negative Return on Equity (-88.99%), as it is currently unprofitable.